HBHyun Woo Baek

Hyun Woo Baek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyun Woo Baek has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Eunjung Han

    Department of Otorhinolaryngology‐Head and Neck Surgery Korea University Ansan Hospital Ansan Gyeonggi Republic of Korea

    2 shared publications
  • June Choi

    Department of Otorhinolaryngology-Head and Neck Surgery, Ansan Hospital, Korea University College of Medicine, Ansan 15208, Republic of Korea

    2 shared publications
  • Kyungtae Hyun

    Department of Otorhinolaryngology‐Head and Neck Surgery Korea University Ansan Hospital Ansan Gyeonggi Republic of Korea

    2 shared publications
  • Dorjsuren Tsagaankhuu

    Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

    1 shared publication
  • Eunjung Han

    Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Ansan Hospital, Ansan-si 15355, Republic of Korea

    1 shared publication
  • Hwee-Jin Kim

    Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Ansan Hospital, Ansan-si 15355, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    Identification of ANC-3 as a Novel Therapeutic Candidate for Anaplastic Thyroid Cancer Through Drug Screening and Multi-Platform Validation

    by Dorjsuren Tsagaankhuu, Hyunwoo Baek, Jungyoon Choi, Soonyoung Kwon

    Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy characterized by rapid progression, early metastasis, and extremely poor survival outcomes. Effective therapeutic options remain limited, highlighting the need for efficient and biologically relevant preclinical drug-discovery platforms. In this study, high-throughput compound screening using human ATC cell lines identified ANC-3 as a potential anticancer candidate. Its antitumor activity was evaluated through cytotoxicity and functional assays, zebrafish xenograft validation with live fluorescence imaging, colony-formation assays, and bulk RNA sequencing with pathway enrichment analyses. ANC-3 demonstrated consistent antitumor effects by significantly inhibiting cell viability, migration, invasion, and clonogenic survival, while also suppressing tumor growth in zebrafish xenograft models. Transcriptomic analyses revealed modulation of multiple oncogenic pathways, including MAPK, Ras, and NF-κB signaling. Collectively, these findings support zebrafish xenograft-based screening as a rapid and scalable platform for ATC drug discovery and suggest ANC-3 as a promising multi-pathway inhibitor warranting further preclinical development.

  • Comprehensive Evaluation of the Embryotoxicity and Ototoxicity of a Car Diffuser on Zebrafish Larvae: Impacts on Morphology and Hair Cells

    by Hyun Woo Baek, Saemi Park, Yeonhwa Kim, Kyungtae Hyun, Sumin Hong, Eunjung Han, Yunkyoung Lee, Hwee‐Jin Kim, Yoon Chan Rah, Suhyun Kim, et al.

    Diffusers release various chemical compounds into the environment, some of which may have ototoxic effects. Despite their widespread use, the safety profiles of these compounds remain largely unexplored. This study evaluated the potential toxicity of a car diffuser extract, Diff3, on zebrafish larvae by assessing morphology, survival rate, hair cell integrity, and rheotactic behavior. Forty wild‐type zebrafish larvae at 4 h post‐fertilization (hpf) were exposed to Diff3 and observed at 3 and 5 days post‐fertilization (dpf) using a stereomicroscope. Hair cell damage was assessed using YO‐PRO‐1 iodide staining in four neuromasts and oxidative stress was measured in transgenic (Brn3C:EGFP) larvae using CellROX Deep Red Reagent. Rheotactic behavior was analyzed using a specialized behavioral testing system. No significant morphological changes or survival differences were observed between groups. However, hair cell counts were significantly reduced in Diff3‐treated larvae, and ROS levels were notably higher in the treatment group. However, in additional experiments, no significant changes in rheotactic behavior were observed. These findings suggest that Diff3 induces hair cell loss through oxidative stress, which may affect sensory function. This study highlights the need to evaluate the ototoxic potential of household chemical products and emphasizes the importance of regulatory measures to ensure consumer safety. Further research is required to determine long‐term effects and potential recovery mechanisms following exposure to such compounds.

  • Open Access

    Protective Effects of (-)-Butaclamol Against Gentamicin-Induced Ototoxicity: In Vivo and In Vitro Approaches

    by Sumin Hong, Eunjung Han, Saemi Park, Kyungtae Hyun, Yunkyoung Lee, Hyun Woo Baek, Hwee-Jin Kim, Yoon Chan Rah, June Choi

    Gentamicin-induced ototoxicity leads to irreversible sensorineural hearing loss due to structural and functional damage to inner ear hair cells. In this study, we identified (-)-butaclamol as a potent protective agent against gentamicin-induced cytotoxicity through high-content screening (HCS) of a natural compound library. (-)-Butaclamol significantly enhanced cell viability in both HEI-OC1 cells and zebrafish neuromasts, demonstrating robust protection against gentamicin toxicity. Mechanistically, (-)-butaclamol inhibited intrinsic apoptosis, as evidenced by reduced TUNEL-positive cell counts and the downregulation of BAX and caspase-3, alongside the upregulation of BCL-2. Moreover, (-)-butaclamol activated key survival signaling pathways, including AKT/mTOR and ERK, while suppressing the inflammatory regulator NF-κB. Additional analyses revealed that (-)-butaclamol effectively mitigated oxidative stress and restored autophagic activity, as confirmed by CellROX and LysoTracker assays. Notably, TMRE staining showed that (-)-butaclamol preserved mitochondrial membrane potential in zebrafish hair cells, indicating mitochondrial protection. Collectively, these findings suggest that (-)-butaclamol exerts comprehensive cytoprotective effects against gentamicin-induced ototoxicity by modulating apoptosis, enhancing survival signaling, and restoring mitochondrial and cellular homeostasis. These results highlight the therapeutic potential of (-)-butaclamol and provide a foundation for future studies aimed at its clinical application.


  • Open Access

    Exploring the Role of the KCNK1 Potassium Channel and Its Inhibition Using Quinidine in Treating Head and Neck Squamous Cell Carcinoma

    by Hyun Woo Baek, Eunjung Han, Kyoung Ho Oh

    Objectives. Our study aimed to explore the role of the potassium channel KCNK1 in head and neck squamous cell carcinoma, focusing on its impact on tumor growth, invasion, and metastasis. We also investigated the therapeutic potential of quinidine, a known KCNK1 inhibitor, in both in vitro cell lines and a zebrafish patient-derived xenograft (PDX) model.Methods. We established primary cell cultures from head and neck cancer tissues and employed the FaDu cell line for in vitro studies, modulating KCNK1 expression through overexpression and knockdown techniques. We evaluated cell migration, invasion, and proliferation. Additionally, we developed a zebrafish PDX model to assess the impact of quinidine on tumor growth and metastasis in vivo. RNA sequencing and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to elucidate the molecular mechanisms underlying the role of KCNK1 in cancer progression.Results. Overexpression of KCNK1 in FaDu cells resulted in enhanced cell migration and invasion, whereas its knockdown diminished these processes. In the zebrafish PDX model, quinidine markedly inhibited tumor growth and metastasis, demonstrating a significant reduction in tumor volume and micrometastasis rates compared to the control groups. The molecular analyses indicated that KCNK1 plays a role in critical signaling pathways associated with tumor growth, such as the Ras and MAPK pathways.Conclusion. Our findings highlight the critical role of KCNK1 in promoting tumor growth and metastasis in head and neck cancer. The inhibitory effect of quinidine on tumor progression in the zebrafish PDX model highlights the therapeutic potential of targeting KCNK1. These results suggest that KCNK1 could serve as a valuable therapeutic target for head and neck cancer, warranting further investigation into treatments that target KCNK1.